Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of ALS. Cytokinetics holds the exclusive right to develop and commercialize tirasemtiv throughout the world. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. Amgen holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and Astellas holds an exclusive license worldwide to develop and commercialize CK-2127107. Both licenses are subject to Cytokinetics' specified development and commercialization participation rights.
Company Growth (employees)
Type
Public
HQ
South San Francisco, US
Founded
1997
Size (employees)
127 (est)+27%
Cytokinetics was founded in 1997 and is headquartered in South San Francisco, US

Cytokinetics Office Locations

Cytokinetics has an office in South San Francisco
South San Francisco, US (HQ)
280 E Grand Ave

Cytokinetics Data and Metrics

Cytokinetics Financial Metrics

Cytokinetics's revenue was reported to be $106.4 m in FY, 2016 which is a 271% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

106.4 m

Revenue growth (FY, 2015 - FY, 2016), %

271%

Net income (FY, 2016)

16.5 m

EBIT (FY, 2016)

18.7 m

Market capitalization (26-May-2017)

635.7 m

Closing share price (26-May-2017)

14.1

Cash (31-Dec-2016)

66.9 m

EV

598.7 m
Cytokinetics's current market capitalization is $635.7 m.
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

30.6 m46.9 m28.7 m106.4 m

Revenue growth, %

53%(39%)271%

R&D expense

49.5 m

General and administrative expense

15.1 m

Operating expense total

64.5 m61.7 m66.1 m87.7 m

EBIT

(33.9 m)(14.8 m)(37.4 m)18.7 m

EBIT margin, %

(111%)(31%)(131%)18%

Interest expense

2.7 m

Interest income

177 k94 k464 k

Pre tax profit

(33.7 m)(14.6 m)(37.5 m)16.5 m

Income tax expense

Net Income

(33.7 m)(14.6 m)(37.5 m)16.5 m
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

20.2 m20.2 m65.1 m66.9 m

Accounts Receivable

Inventories

Current Assets

79.3 m131.1 m113.1 m158.6 m

PP&E

1.2 m1.6 m1.8 m3.6 m

Total Assets

83.2 m133 m115.2 m170.1 m

Accounts Payable

3.7 m1.4 m2.2 m4.2 m

Total Debt

29.9 m

Current Liabilities

26.7 m23.9 m31.6 m33.3 m

Additional Paid-in Capital

537 m589.3 m603.1 m612.5 m

Retained Earnings

(482.6 m)(497.2 m)(534.7 m)(518.3 m)

Total Equity

54.4 m92.1 m68.6 m94.4 m

Debt to Equity Ratio

0.3 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.5 x1.4 x1.7 x1.8 x
Numbers are in $, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(33.7 m)(14.6 m)(37.5 m)16.5 m

Accounts Receivable

Inventories

Accounts Payable

1.7 m(2.2 m)755 k1.7 m

Cash From Operating Activities

(7.7 m)(44.8 m)4.9 m37 m

Purchases of PP&E

(542 k)(1.1 m)(562 k)(1.6 m)

Cash From Investing Activities

(1.5 m)(4 m)16.1 m(52.1 m)

Cash From Financing Activities

14.5 m48.9 m23.9 m16.9 m
Y, 2016

EV/EBIT

32 x

EV/CFO

16.2 x

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.8 x

Cytokinetics Market Value History

Cytokinetics Job Categories

Cytokinetics Online and Social Media Presence

Cytokinetics Company Life and Culture

You may also be interested in